Supplementary Figure 7



Supplementary Figure 7 – **SMAP-061 show no toxicity effects *in vivo*, having no significant impact on mouse body weight.** A) OV81, B) OV262.2 and C) OV17.1 PDX studies were conducted with tumors implanted in the right flank of NSG mice and allowed to grow between ~80-250mm^3 before enrollment in one of 4 treatment groups: Vehicle control, SMAP-061, Olaparib or SMAP + Olaparib combination. Mouse body weights were measured every other day. Data plotted as a function of time and presented as mean ± SEM (Student T-tests, comparing each treatment group relative to vehicle control, *$p < 0.05$, **$p < 0.01$). D) Quantification of *in vivo* γH2Ax foci formation for C) OV81, E) OV262 and F) OV17 were calculated from Fig. 6C, 6F and 6I, respectively. Data presented as mean ± SEM (Student T-tests, comparing each treatment group relative to vehicle control, **$p < 0.01$, ***$p < 0.001$).